Current Status of Imatinib as Frontline Therapy for Chronic Myeloid Leukemia

被引：23

作者：

Marin, David ^{[1
]}

机构：

[1] Univ London Imperial Coll Sci Technol & Med, Dept Haematol, Hammersmith Hosp, London W12 0NN, England

来源：

SEMINARS IN HEMATOLOGY | 2010年 / 47卷 / 04期

关键词：

CHRONIC MYELOGENOUS LEUKEMIA; PATIENTS RECEIVING IMATINIB; MAJOR CYTOGENETIC RESPONSE; GENE-EXPRESSION SIGNATURE; KINASE DOMAIN MUTATIONS; STANDARD-DOSE IMATINIB; CHRONIC-PHASE; INTERFERON-ALPHA; HIGH-RISK; PROGNOSTIC DISCRIMINATION;

D O I：

10.1053/j.seminhematol.2010.06.003

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Imatinib is remarkably effective in treating newly diagnosed patients with chronic myeloid leukemia (CML) in chronic phase. However, at 5 years more than one third of the patients have abandoned the medication on account of side effects, lack of efficacy, or progression. Here we review the current results with imatinib, the prognostic factors for response, and issues associated with long-term treatment with imatinib such as pregnancy, adherence to therapy, and complete molecular responses. Semin Hematol 47:312-318. (C) 2010 Elsevier Inc. All rights reserved.

引用

页码：312 / 318

页数：7

共 52 条

[1] UK MEDICAL-RESEARCH-COUNCIL RANDOMIZED, MULTICENTER TRIAL OF INTERFERON-ALPHA-N1 FOR CHRONIC MYELOID-LEUKEMIA - IMPROVED SURVIVAL IRRESPECTIVE OF CYTOGENETIC RESPONSE [J].

ALLAN, NC ;

RICHARDS, SM ;

SHEPHERD, PCA .

LANCET, 1995, 345 (8962) :1392-1397

[2] HLA-Identical Sibling Compared With 8/8 Matched and Mismatched Unrelated Donor Bone Marrow Transplant for Chronic Phase Chronic Myeloid Leukemia [J].

Arora, Mukta ;

Weisdorf, Daniel J. ;

Spellman, Stephen R. ;

Haagenson, Michael D. ;

Klein, John P. ;

Hurley, Carolyn K. ;

Selby, George B. ;

Antin, Joseph H. ;

Kernan, Nancy A. ;

Kollman, Craig ;

Nademanee, Auayporn ;

McGlave, Philip ;

Horowitz, Mary M. ;

Petersdorf, Effie W. .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (10) :1644-1652

[3] Pregnancy among patients with chronic myeloid leukemia treated with imatinib [J].

Ault, P ;

Kantarjian, H ;

O'Brien, S ;

Faderl, S ;

Beran, M ;

Rios, MB ;

Koller, C ;

Giles, F ;

Keating, M ;

Talpaz, M ;

Cortes, J .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (07) :1204-1208

[4] Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet [J].

Baccarani, Michele ;

Cortes, Jorge ;

Pane, Fabrizio ;

Niederwieser, Dietger ;

Saglio, Giuseppe ;

Apperley, Jane ;

Cervantes, Francisco ;

Deininger, Michael ;

Gratwohl, Alois ;

Guilhot, Francois ;

Hochhaus, Andreas ;

Horowitz, Mary ;

Hughes, Timothy ;

Kantarjian, Hagop ;

Larson, Richard ;

Radich, Jerald ;

Simonsson, Bengt ;

Silver, Richard T. ;

Goldman, John ;

Hehlmann, Rudiger .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (35) :6041-6051

[5] Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study [J].

Baccarani, Michele ;

Rosti, Gianantonio ;

Castagnetti, Fausto ;

Haznedaroglu, Ibrahim ;

Porkka, Kimmo ;

Abruzzese, Elisabetta ;

Alimena, Giuliana ;

Ehrencrona, Hans ;

Hjorth-Hansen, Henrik ;

Kairisto, Veli ;

Levato, Luciano ;

Martinelli, Giovanni ;

Nagler, Arnon ;

Nielsen, Johan Lanng ;

Ozbek, Ugur ;

Palandri, Francesca ;

Palmieri, Fausto ;

Pane, Fabrizio ;

Rege-Cambrin, Giovanna ;

Russo, Domenico ;

Specchia, Giorgina ;

Testoni, Nicoletta ;

Weiss-Bjerrum, Ole ;

Saglio, Giuseppe ;

Simonsson, Bengt .

BLOOD, 2009, 113 (19) :4497-4504

[6] Chronic myeloid leukemia and interferon-α:: a study of complete cytogenetic responders [J].

Bonifazi, F ;

de Vivo, A ;

Rosti, G ;

Guilhot, F ;

Guilhot, J ;

Trabacchi, E ;

Hehlmann, R ;

Hochhaus, A ;

Shepherd, PCA ;

Steegmann, JL ;

Kluin-Nelemans, HC ;

Thaler, J ;

Simonsson, B ;

Louwagie, A ;

Reiffers, J ;

Mahon, FX ;

Montefusco, E ;

Alimena, G ;

Hasford, J ;

Richards, S ;

Saglio, G ;

Testoni, N ;

Martinelli, G ;

Tura, S ;

Baccarani, M .

BLOOD, 2001, 98 (10) :3074-3081

[7] Phase III, Randomized, Open-Label Study of Daily Imatinib Mesylate 400 mg Versus 800 mg in Patients With Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase Using Molecular End Points: Tyrosine Kinase Inhibitor Optimization and Selectivity Study [J].

Cortes, Jorge E. ;

Baccarani, Michele ;

Guilhot, Francois ;

Druker, Brian J. ;

Branford, Susan ;

Kim, Dong-Wook ;

Pane, Fabrizio ;

Pasquini, Ricardo ;

Goldberg, Stuart L. ;

Kalaycio, Matt ;

Moiraghi, Beatriz ;

Rowe, Jacob M. ;

Tothova, Elena ;

De Souza, Carmino ;

Rudoltz, Marc ;

Yu, Richard ;

Krahnke, Tillmann ;

Kantarjian, Hagop M. ;

Radich, Jerald P. ;

Hughes, Timothy P. .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (03) :424-430

[8] Nilotinib As Front-Line Treatment for Patients With Chronic Myeloid Leukemia in Early Chronic Phase [J].

Cortes, Jorge E. ;

Jones, Dan ;

O'Brien, Susan ;

Jabbour, Elias ;

Konopleva, Marina ;

Ferrajoli, Alessandra ;

Kadia, Tapan ;

Borthakur, Gautam ;

Stigliano, Denise ;

Shan, Jianqin ;

Kantarjian, Hagop .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (03) :392-397

[9] Results of Dasatinib Therapy in Patients With Early Chronic-Phase Chronic Myeloid Leukemia [J].

Cortes, Jorge E. ;

Jones, Dan ;

O'Brien, Susan ;

Jabbour, Elias ;

Ravandi, Farhad ;

Koller, Charles ;

Borthakur, Gautam ;

Walker, Brenda ;

Zhao, Weiqiang ;

Shan, Jianqin ;

Kantarjian, Hagop .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (03) :398-404

[10] International standardisation of quantitative real-time RT-PCR for BCR-ABL [J].

Cross, Nicholas C. P. ;

Hughes, Timothy P. ;

Hochhaus, Andreas ;

Goldman, John M. .

LEUKEMIA RESEARCH, 2008, 32 (03) :505-506

← 1 2 3 4 5 6 →